• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

来自旧世界灵长类动物 1 型疱疹病毒的 TAP 抑制剂及其用途:WO2009008713.

TAP-inhibitors from old world primate 1-herpesviruses and their use: WO2009008713.

机构信息

University of Michigan Medical School, Department of Microbiology and Immunology, 5641 Medical Science Building II, Ann Arbor, MI 48109-5620, USA.

出版信息

Expert Opin Ther Pat. 2010 Feb;20(2):277-82. doi: 10.1517/13543770903501563.

DOI:10.1517/13543770903501563
PMID:20100007
Abstract

Cytotoxic T lymphocytes (CTLs) recognize peptide antigens in the context of major histocompatibility complex (MHC) class I molecules. CTL-mediated immunity is important for defense against cancers and virus infections, and thus viruses and tumors have evolved CTL-evasion mechanisms. The transporter associated with antigen processing (TAP) is a key factor for MHC class I assembly, and TAP is a frequent target of immune evasion by viruses and tumors. WO2009008713 discloses potential therapeutic uses of TAP inhibitors encoded by Epstein-Barr virus and its lymphocryptovirus (LCV) homologs. In particular, WO2009008713 proposes the use of LCV TAP inhibitors and their combinations with other viral TAP inhibitors to elicit novel categories of CTLs that destroy target cells in which the function of TAP or other components of the MHC class I assembly pathway is inhibited. Alternatively, WO2009008713 proposes the use of LCV TAP inhibitors and their combinations with other viral TAP inhibitors to more efficiently generate tumor-specific T-cell epitopes for immunotherapy. The methods described in WO2009008713 offer the promise of new strategies of cancer immunotherapy. However, significant optimization of therapy conditions and characterizations of eligible tumor types will be needed to further develop therapeutic use of TAP inhibitors.

摘要

细胞毒性 T 淋巴细胞 (CTL) 通过主要组织相容性复合体 (MHC) I 类分子识别肽抗原。CTL 介导的免疫对于防御癌症和病毒感染很重要,因此病毒和肿瘤已经进化出 CTL 逃逸机制。抗原加工相关转运蛋白 (TAP) 是 MHC I 类组装的关键因素,TAP 是病毒和肿瘤免疫逃逸的常见靶点。WO2009008713 公开了 Epstein-Barr 病毒及其淋巴隐病毒 (LCV) 同源物编码的 TAP 抑制剂的潜在治疗用途。特别是,WO2009008713 提出了使用 LCV TAP 抑制剂及其与其他病毒 TAP 抑制剂的组合,以引发新类别的 CTL,破坏 TAP 或 MHC I 组装途径其他成分的功能受到抑制的靶细胞。或者,WO2009008713 提出使用 LCV TAP 抑制剂及其与其他病毒 TAP 抑制剂的组合,以更有效地产生用于免疫治疗的肿瘤特异性 T 细胞表位。WO2009008713 中描述的方法为癌症免疫治疗提供了新策略的希望。然而,需要对治疗条件进行重大优化,并对合格的肿瘤类型进行特征描述,以进一步开发 TAP 抑制剂的治疗用途。

相似文献

1
TAP-inhibitors from old world primate 1-herpesviruses and their use: WO2009008713.来自旧世界灵长类动物 1 型疱疹病毒的 TAP 抑制剂及其用途:WO2009008713.
Expert Opin Ther Pat. 2010 Feb;20(2):277-82. doi: 10.1517/13543770903501563.
2
Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies.肽转运体(TAP-1和TAP-2)非依赖性的爱泼斯坦-巴尔病毒(EBV)潜伏膜蛋白2A的内源性加工:对EBV相关恶性肿瘤细胞毒性T淋巴细胞控制的影响
J Virol. 1996 Aug;70(8):5357-62. doi: 10.1128/JVI.70.8.5357-5362.1996.
3
Inhibition of mouse TAP by immune evasion molecules encoded by non-murine herpesviruses.非鼠类疱疹病毒编码的免疫逃逸分子对小鼠 TAP 的抑制作用。
Mol Immunol. 2011 Mar;48(6-7):835-45. doi: 10.1016/j.molimm.2010.12.008. Epub 2011 Feb 2.
4
The varicellovirus-encoded TAP inhibitor UL49.5 regulates the presentation of CTL epitopes by Qa-1b1.水痘病毒编码的TAP抑制剂UL49.5通过Qa-1b1调节CTL表位的呈递。
J Immunol. 2007 Jan 15;178(2):657-62. doi: 10.4049/jimmunol.178.2.657.
5
Viral interference with antigen presentation: trapping TAP.病毒对抗原呈递的干扰:TAP 的捕获。
Mol Immunol. 2013 Sep;55(2):139-42. doi: 10.1016/j.molimm.2012.10.009. Epub 2012 Nov 8.
6
Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on epstein-barr virus-specific cytotoxic T-cell recognition.霍奇金-里德-斯腾伯格细胞的抗原呈递表型:HLA I类加工途径分析及白细胞介素-10对爱泼斯坦-巴尔病毒特异性细胞毒性T细胞识别的影响
Blood. 1998 Aug 1;92(3):1020-30.
7
Viral inhibition of the transporter associated with antigen processing (TAP): a striking example of functional convergent evolution.病毒对抗原加工相关转运体(TAP)的抑制:功能趋同进化的一个显著例子。
PLoS Pathog. 2015 Apr 16;11(4):e1004743. doi: 10.1371/journal.ppat.1004743. eCollection 2015 Apr.
8
Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway.一种跨膜多次的爱泼斯坦-巴尔病毒蛋白用于CD8(+) T细胞识别的加工过程揭示了一条蛋白酶体依赖性、与抗原加工无关的转运体相关途径。
J Exp Med. 2001 Oct 15;194(8):1053-68. doi: 10.1084/jem.194.8.1053.
9
Defective presentation of MHC class I-restricted cytotoxic T-cell epitopes in Burkitt's lymphoma cells.伯基特淋巴瘤细胞中MHC I类限制性细胞毒性T细胞表位呈递缺陷。
Int J Cancer. 1996 Oct 9;68(2):251-8. doi: 10.1002/(SICI)1097-0215(19961009)68:2<251::AID-IJC19>3.0.CO;2-D.
10
Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.爱泼斯坦-巴尔病毒潜伏膜蛋白1恢复伯基特淋巴瘤细胞内源性抗原加工:肽转运体和HLA-I类抗原表达的协同上调
Eur J Immunol. 1995 May;25(5):1374-84. doi: 10.1002/eji.1830250536.

引用本文的文献

1
Transformation of SV40-immortalized human uroepithelial cells by 3-methylcholanthrene increases IFN- and Large T Antigen-induced transcripts.3-甲基胆蒽转化 SV40 永生化人尿路上皮细胞增加 IFN- 和大 T 抗原诱导的转录物。
Cancer Cell Int. 2010 Feb 23;10:4. doi: 10.1186/1475-2867-10-4.